154 related articles for article (PubMed ID: 18041671)
1. MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases.
Dudich E
Curr Opin Mol Ther; 2007 Dec; 9(6):603-10. PubMed ID: 18041671
[TBL] [Abstract][Full Text] [Related]
2. XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator.
van Eden W
Curr Opin Investig Drugs; 2008 May; 9(5):523-33. PubMed ID: 18465663
[TBL] [Abstract][Full Text] [Related]
3. IDEC-114 (IDEC).
Schopf RE
Curr Opin Investig Drugs; 2001 May; 2(5):635-8. PubMed ID: 11569938
[TBL] [Abstract][Full Text] [Related]
4. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
Ding C
Curr Opin Investig Drugs; 2006 Nov; 7(11):1020-5. PubMed ID: 17117592
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of the studies. Important recombinant agents in treatment of rheumatoid arthritis].
Kaltwasser JP
Pharm Unserer Zeit; 2003; 32(5):396-403. PubMed ID: 14526460
[No Abstract] [Full Text] [Related]
6. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
7. Worldwide experience with Sandimmune (cyclosporine) in autoimmune diseases: multiple sclerosis, rheumatoid arthritis, psoriasis.
Carstens J
Mt Sinai J Med; 1990 Oct; 57(5):311-4. PubMed ID: 2096278
[No Abstract] [Full Text] [Related]
8. Technology evaluation: SB-485232, GlaxoSmithKline.
Golab J; Stoklosa T
Curr Opin Mol Ther; 2005 Feb; 7(1):85-93. PubMed ID: 15732534
[TBL] [Abstract][Full Text] [Related]
9. Effects of methotrexate use in a patient with rheumatoid arthritis and multiple sclerosis.
Li S; Kaur PP; Berney SN
J Clin Rheumatol; 2008 Aug; 14(4):241-2. PubMed ID: 18766127
[TBL] [Abstract][Full Text] [Related]
10. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding C; Xu J; Li J
Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
[TBL] [Abstract][Full Text] [Related]
11. rAAt (dermatological) Arriva/ProMetic.
Brown WM
Curr Opin Mol Ther; 2006 Feb; 8(1):69-75. PubMed ID: 16506528
[TBL] [Abstract][Full Text] [Related]
12. Drug evaluation: the C5a receptor antagonist PMX-53.
Köhl J
Curr Opin Mol Ther; 2006 Dec; 8(6):529-38. PubMed ID: 17243489
[TBL] [Abstract][Full Text] [Related]
13. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis.
Murakami Y; Akahoshi T; Aoki N; Toyomoto M; Miyasaka N; Kohsaka H
Arthritis Rheum; 2009 Jun; 60(6):1615-23. PubMed ID: 19479878
[TBL] [Abstract][Full Text] [Related]
14. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
Fleischmann RM
Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
[TBL] [Abstract][Full Text] [Related]
15. Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et al.
Epstein WV
Arthritis Rheum; 1999 Aug; 42(8):1781-2. PubMed ID: 10446884
[No Abstract] [Full Text] [Related]
16. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia.
Longhurst H
Curr Opin Investig Drugs; 2008 Mar; 9(3):310-23. PubMed ID: 18311668
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Hutas G
Curr Opin Investig Drugs; 2008 Nov; 9(11):1206-15. PubMed ID: 18951300
[TBL] [Abstract][Full Text] [Related]
18. Technology evaluation: Belatacept, Bristol-Myers Squibb.
Vanhove B; Soulillou JP
Curr Opin Mol Ther; 2005 Aug; 7(4):384-93. PubMed ID: 16121705
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune diseases induced by TNF-targeted therapies.
Ramos-Casals M; Brito-Zerón P; Soto MJ; Cuadrado MJ; Khamashta MA
Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):847-61. PubMed ID: 19028367
[TBL] [Abstract][Full Text] [Related]
20. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
Burnett JR
Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
